Axsome Therapeutics faces competition amid FDA review risk for Summit's ivonescimab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Source: Fool
Axsome Therapeutics Inc. saw its stock price drop by 5.00% as it crossed below the 5-day SMA amid a challenging market environment, with the Nasdaq-100 down 1.88% and the S&P 500 down 1.60%.
The decline in Axsome's stock is influenced by the competitive landscape in the biotech sector, particularly with Summit Therapeutics facing FDA review risks for ivonescimab. Although Axsome reported a 65.5% revenue increase in 2025, the uncertainty surrounding Summit's drug approval could impact investor sentiment and market dynamics, leading to a potential sector rotation.
Investors are closely monitoring the developments in the biotech industry, especially as Axsome awaits FDA approval for its Alzheimer's drug AXS-05, which could enhance its market position. The competition with Summit and Madrigal Pharmaceuticals highlights the need for Axsome to maintain its growth momentum.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXSM
Wall Street analysts forecast AXSM stock price to fall
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 252.160
Low
153.00
Averages
209.54
High
260.00
Current: 252.160
Low
153.00
Averages
209.54
High
260.00
About AXSM
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Axsome Promotes Alzheimer's Awareness During Awareness Month
- Impact of Alzheimer's Disease: Over 7 million individuals in the U.S. are affected by Alzheimer's disease, with projections indicating this number could rise to approximately 13 million by 2050, highlighting the significant impact on patients and nearly 13 million family members, thus underscoring the importance of brain health awareness and support.
- Community Engagement Activities: Axsome is set to participate in more than 30 Walk to End Alzheimer's® events in New York City, aiming to raise public awareness about Alzheimer's disease and encourage individuals to adopt daily habits that support brain health.
- Headquarters Lighting Event: Axsome's headquarters at One World Trade Center will be lit in purple on June 21 through the Spireworks program, symbolizing support for Alzheimer's patients and further enhancing public focus on the disease.
- Collaboration with Advocacy Organizations: Axsome is partnering with various advocacy and patient organizations to provide resources and support for individuals and families affected by Alzheimer's disease, demonstrating the company's commitment to promoting brain health and disease awareness.
See More
Three Innovative Biotechs with Promising Prospects
- Madrigal Approval: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis, addressing the urgent needs of millions of patients in the U.S., and is expected to see significant revenue growth over the next decade.
- Axsome Sales Surge: Axsome Therapeutics reported first-quarter sales of $153.2 million for its Auvelity drug, a 59% year-over-year increase, and has received label expansion for treating Alzheimer's disease agitation, projecting peak sales of $8 billion in the future.
- Kailera's Market Potential: Kailera Therapeutics focuses on developing weight loss medications and, despite not having marketed products, its leading candidate ribupatide is currently in phase 3 trials, potentially positioning it well in the rapidly growing anti-obesity market.
- Investment Risks and Opportunities: While Madrigal and Axsome face competition and regulatory risks, their market prospects and pipeline potential make them attractive for investors, particularly for those looking at long-term investments in the biotech sector.
See More
Analysis of Three Promising Biotech Companies
- Madrigal Pharmaceuticals Breakthrough: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first medicine for metabolic dysfunction-associated steatohepatitis, with over 42,250 patients treated and a 127% year-over-year revenue increase to $311.3 million in Q1, indicating strong market demand and growth potential.
- Axsome Therapeutics Progress: Axsome Therapeutics' Auvelity achieved $153.2 million in sales in Q1, a 59% increase year-over-year, and received label expansion for treating Alzheimer's disease agitation, with projected peak sales of $8 billion, showcasing its robust growth potential in mental health.
- Kailera Risks and Opportunities: Kailera Therapeutics focuses on developing weight loss medications and, despite having no marketed products, its leading candidate ribupatide is in phase 3 trials, potentially positioning it in the rapidly growing anti-obesity market, appealing to risk-tolerant investors.
- Market Competition and Challenges: While Madrigal and Axsome excel in their respective fields, they face competition from large pharmaceutical companies like Novo Nordisk, and Kailera's lack of marketed products increases investment risk, necessitating careful evaluation of potential clinical and regulatory challenges.
See More
Axsome Presents New SYMBRAVO Data at AHS Meeting
- New Data Presentation: Axsome Therapeutics showcased new SYMBRAVO® data at the American Headache Society annual meeting, covering multiple studies on acute migraine treatment, highlighting its market potential and clinical value.
- Clinical Trial Results: SYMBRAVO demonstrated sustained pain relief in the MOMENTUM and MOVEMENT trials, indicating its effectiveness in acute migraine treatment, which could drive market acceptance and sales growth.
- Comparative Analysis: A network meta-analysis comparing SYMBRAVO with Gepants further validated its efficacy, enhancing its competitiveness and potentially attracting more attention from healthcare providers.
- Strategic Implications: This data presentation not only underscores Axsome's leadership in the CNS field but also lays the groundwork for future product development and market expansion, further elevating the company's influence in the biopharmaceutical industry.
See More
Axsome Therapeutics Settles Patent Litigation for SUNOSI
- Patent Litigation Settlement: Axsome Therapeutics announced a settlement with the last first-to-file generic applicant, resolving all patent litigation related to its product SUNOSI, marking a significant legal victory for the company.
- Generic Sales Rights: Under the settlement terms, Axsome will grant five companies the right to sell generic versions of SUNOSI starting on March 1, 2040, or September 1, 2040, if pediatric exclusivity is granted, further solidifying its market position.
- Market Exclusivity Assurance: This settlement provides long-term clarity for SUNOSI's market exclusivity, allowing Axsome to focus on expanding its CNS pipeline and advancing therapies for conditions affecting millions of patients.
- Stock Performance: Axsome's stock has traded between $96.09 and $238.56 over the past year, closing at $233.49 on Wednesday with a 5.10% increase, reflecting positive market sentiment regarding the settlement.
See More
Axsome Therapeutics Settles Patent Lawsuits for Sunosi
- Patent Lawsuit Resolution: Axsome Therapeutics announced the settlement of all patent lawsuits related to its sleep disorder therapy Sunosi, ensuring market stability and boosting investor confidence.
- Market Access Rights: As a result of the agreements, five companies will gain rights to sell generic versions of Sunosi by 2040, positioning Axsome for long-term competitive advantages in the market.
- Sales Performance: Sunosi generated $120.1 million in net sales last year, accounting for nearly 19% of Axsome's total product sales, demonstrating strong market performance.
- Future Outlook: Axsome projects peak sales of its new drug Auvelity to reach at least $8 billion following approval for agitation in Alzheimer's disease, further solidifying the company's market position.
See More
Axsome Promotes Alzheimer's Awareness During Awareness Month
- Impact of Alzheimer's Disease: Over 7 million individuals in the U.S. are affected by Alzheimer's disease, with projections indicating this number could rise to approximately 13 million by 2050, highlighting the significant impact on patients and nearly 13 million family members, thus underscoring the importance of brain health awareness and support.
- Community Engagement Activities: Axsome is set to participate in more than 30 Walk to End Alzheimer's® events in New York City, aiming to raise public awareness about Alzheimer's disease and encourage individuals to adopt daily habits that support brain health.
- Headquarters Lighting Event: Axsome's headquarters at One World Trade Center will be lit in purple on June 21 through the Spireworks program, symbolizing support for Alzheimer's patients and further enhancing public focus on the disease.
- Collaboration with Advocacy Organizations: Axsome is partnering with various advocacy and patient organizations to provide resources and support for individuals and families affected by Alzheimer's disease, demonstrating the company's commitment to promoting brain health and disease awareness.
See More
Three Innovative Biotechs with Promising Prospects
- Madrigal Approval: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis, addressing the urgent needs of millions of patients in the U.S., and is expected to see significant revenue growth over the next decade.
- Axsome Sales Surge: Axsome Therapeutics reported first-quarter sales of $153.2 million for its Auvelity drug, a 59% year-over-year increase, and has received label expansion for treating Alzheimer's disease agitation, projecting peak sales of $8 billion in the future.
- Kailera's Market Potential: Kailera Therapeutics focuses on developing weight loss medications and, despite not having marketed products, its leading candidate ribupatide is currently in phase 3 trials, potentially positioning it well in the rapidly growing anti-obesity market.
- Investment Risks and Opportunities: While Madrigal and Axsome face competition and regulatory risks, their market prospects and pipeline potential make them attractive for investors, particularly for those looking at long-term investments in the biotech sector.
See More
Analysis of Three Promising Biotech Companies
- Madrigal Pharmaceuticals Breakthrough: Madrigal Pharmaceuticals made history in 2024 by earning approval for Rezdiffra, the first medicine for metabolic dysfunction-associated steatohepatitis, with over 42,250 patients treated and a 127% year-over-year revenue increase to $311.3 million in Q1, indicating strong market demand and growth potential.
- Axsome Therapeutics Progress: Axsome Therapeutics' Auvelity achieved $153.2 million in sales in Q1, a 59% increase year-over-year, and received label expansion for treating Alzheimer's disease agitation, with projected peak sales of $8 billion, showcasing its robust growth potential in mental health.
- Kailera Risks and Opportunities: Kailera Therapeutics focuses on developing weight loss medications and, despite having no marketed products, its leading candidate ribupatide is in phase 3 trials, potentially positioning it in the rapidly growing anti-obesity market, appealing to risk-tolerant investors.
- Market Competition and Challenges: While Madrigal and Axsome excel in their respective fields, they face competition from large pharmaceutical companies like Novo Nordisk, and Kailera's lack of marketed products increases investment risk, necessitating careful evaluation of potential clinical and regulatory challenges.
See More
Axsome Presents New SYMBRAVO Data at AHS Meeting
- New Data Presentation: Axsome Therapeutics showcased new SYMBRAVO® data at the American Headache Society annual meeting, covering multiple studies on acute migraine treatment, highlighting its market potential and clinical value.
- Clinical Trial Results: SYMBRAVO demonstrated sustained pain relief in the MOMENTUM and MOVEMENT trials, indicating its effectiveness in acute migraine treatment, which could drive market acceptance and sales growth.
- Comparative Analysis: A network meta-analysis comparing SYMBRAVO with Gepants further validated its efficacy, enhancing its competitiveness and potentially attracting more attention from healthcare providers.
- Strategic Implications: This data presentation not only underscores Axsome's leadership in the CNS field but also lays the groundwork for future product development and market expansion, further elevating the company's influence in the biopharmaceutical industry.
See More
Axsome Therapeutics Settles Patent Litigation for SUNOSI
- Patent Litigation Settlement: Axsome Therapeutics announced a settlement with the last first-to-file generic applicant, resolving all patent litigation related to its product SUNOSI, marking a significant legal victory for the company.
- Generic Sales Rights: Under the settlement terms, Axsome will grant five companies the right to sell generic versions of SUNOSI starting on March 1, 2040, or September 1, 2040, if pediatric exclusivity is granted, further solidifying its market position.
- Market Exclusivity Assurance: This settlement provides long-term clarity for SUNOSI's market exclusivity, allowing Axsome to focus on expanding its CNS pipeline and advancing therapies for conditions affecting millions of patients.
- Stock Performance: Axsome's stock has traded between $96.09 and $238.56 over the past year, closing at $233.49 on Wednesday with a 5.10% increase, reflecting positive market sentiment regarding the settlement.
See More
Axsome Therapeutics Settles Patent Lawsuits for Sunosi
- Patent Lawsuit Resolution: Axsome Therapeutics announced the settlement of all patent lawsuits related to its sleep disorder therapy Sunosi, ensuring market stability and boosting investor confidence.
- Market Access Rights: As a result of the agreements, five companies will gain rights to sell generic versions of Sunosi by 2040, positioning Axsome for long-term competitive advantages in the market.
- Sales Performance: Sunosi generated $120.1 million in net sales last year, accounting for nearly 19% of Axsome's total product sales, demonstrating strong market performance.
- Future Outlook: Axsome projects peak sales of its new drug Auvelity to reach at least $8 billion following approval for agitation in Alzheimer's disease, further solidifying the company's market position.
See More
